Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company’s stock, valued at $7,193,468.91. This represents a 10.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Hims & Hers Health Stock Performance
Shares of Hims & Hers Health stock opened at $33.85 on Thursday. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 76.94 and a beta of 1.37. The stock has a 50 day moving average price of $38.88 and a 200-day moving average price of $28.52. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Trading of Hims & Hers Health
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on HIMS shares. Truist Financial increased their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Piper Sandler raised their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. TD Cowen restated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Citigroup reaffirmed a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.31.
Check Out Our Latest Report on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Why is the Ex-Dividend Date Significant to Investors?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Why Are These Companies Considered Blue Chips?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- What is a Secondary Public Offering? What Investors Need to Know
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.